Subscribe To
NBSE / Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?
NBSE News
By Zacks Investment Research
September 7, 2023
NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake
With NeuBase (NBSE) exploring strategic alternatives to the company, Symetryx joins the company's shareholder base and urges the board to issue a uniq more_horizontal
By InvestorPlace
September 6, 2023
Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?
NeuBase Therapeutics (NASDAQ: NBSE ) stock is taking off on Wednesday despite a lack of news from the preclinical biopharmaceutical company. There ar more_horizontal
By Zacks Investment Research
January 20, 2023
What Makes NeuBase (NBSE) a New Strong Buy Stock
NeuBase (NBSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). more_horizontal
By GlobeNewsWire
March 7, 2022
NeuBase to Present at Oppenheimer's 32nd Annual Healthcare Conference
PITTSBURGH and CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotech more_horizontal
By GlobeNewsWire
March 7, 2022
NeuBase to Present at Oppenheimer's 32nd Annual Healthcare Conference
PITTSBURGH and CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotech more_horizontal
By GlobeNewsWire
March 7, 2022
NeuBase to Present at Oppenheimer's 32nd Annual Healthcare Conference
PITTSBURGH and CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotech more_horizontal